|
2022 Other Outputs Peptide AntibioticsMatthew Cooper, Mark Blaskovich, Alejandra Gallardo-Godoy, Karl Hansford, Alysha Elliott, Carig Muldoon and Bernd Becker (2022). Peptide Antibiotics. US11279733. |
|
2021 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2021). Antibacterial Agents. CN107027309. |
|
2021 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2021). Antibacterial Agents. US10947271. |
|
2020 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2020). Antibacterial Agents. EP3105244. |
|
2019 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2019). Antibacterial Agents. JP6602318. |
|
2019 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2019). Antibacterial Agents. AU2015/213478. |
|
2019 Other Outputs Peptide antibioticsGallardo-Goday, Alejandra, Cooper, Matthew, Blaskovich, Mark, Hansford, Karl and Elliott, Alysha (2019). Peptide antibiotics. WO2019084628. |
|
2018 Other Outputs Visualisation ConstructsMark Blaskovich, Matt Cooper, Mark Butler, Rhia Stone and Wanida Phetsang (2018). Visualisation Constructs. WO/2018/102890. |
|
2018 Other Outputs Glycopeptide Antibiotic ConstructsMark Blaskovich, Matt Cooper, Andrea Ranzoni, Wanida Phetsang and Marwa Hassan (2018). Glycopeptide Antibiotic Constructs. WO/2018/102889. |
|
2016 Other Outputs Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptorMark Arnold Thomas Blaskovich and Peter Joseph Cassidy (2016). Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor. US9340517. |
|
2015 Other Outputs Antibacterial AgentsCooper, Matthew and Blaskovich, Mark (2015). Antibacterial Agents. WO/2015/117196. |
|
2013 Other Outputs 3-Substituted-1,4-Diazepan-2-One Melanocortin-5 Receptor AntagonistsMark Arnold Thomas Blaskovich and Pater Joseph Cassidy (2013). 3-Substituted-1,4-Diazepan-2-One Melanocortin-5 Receptor Antagonists. US8440653 . |
|
2013 Other Outputs Methods of Modulating The Activity of the MC5 Receptor and Treatment of Conditions Related to This ReceptorMark Arnold Thomas Blaskovich and Peter Joseph Cassidy (2013). Methods of Modulating The Activity of the MC5 Receptor and Treatment of Conditions Related to This Receptor. US8377925. |
|
2013 Other Outputs “3-Aminoalkyl-1,4-Diazepan-2-One Melanocortin-5 Receptor AntagonistsMark Arnold Thomas Blaskovich and Peter Joseph Cassidy (2013). “3-Aminoalkyl-1,4-Diazepan-2-One Melanocortin-5 Receptor Antagonists. US8343958. |
|
2011 Other Outputs 3-Aminoalkyl-1,4-Diazepan-2-One Melanocortin-5 Receptor AntagonistsMark Arnold Thomas Blaskovich and Peter Joseph Cassidy (2011). 3-Aminoalkyl-1,4-Diazepan-2-One Melanocortin-5 Receptor Antagonists. US8008291. |
|
2010 Other Outputs Protein Tyrosine Phosphatase Inhibitors and Methods of Use ThereofMark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, Maher Qabar, Lauri Marie Schultz, Feng Hong, William Pratt, Gangadhar Nagula, Jennifer Lynn Gage and James Jeffry Howbert (2010). Protein Tyrosine Phosphatase Inhibitors and Methods of Use Thereof. US7829737. |
|
2010 Other Outputs Modulating the activity of a receptor comprising melanocortin-3 receptor or melanocortin-4 receptor, comprises exposing the receptor to 1,4-diazepan-2-one compoundsBlaskovich, Mark and CASSIDY P J (2010). Modulating the activity of a receptor comprising melanocortin-3 receptor or melanocortin-4 receptor, comprises exposing the receptor to 1,4-diazepan-2-one compounds. WO2010096854-A1. |
|
2010 Other Outputs Modulating activity of melanocortin-1 receptor, delivering active agent to melanocortin-1 receptor, and for treating condition e.g. hyperpigmentation, and pain involves exposing melanocortin-1 receptor to substituted (1,4)diazepane compoundBlaskovich, Mark and CASSIDY P J (2010). Modulating activity of melanocortin-1 receptor, delivering active agent to melanocortin-1 receptor, and for treating condition e.g. hyperpigmentation, and pain involves exposing melanocortin-1 receptor to substituted (1,4)diazepane compound. WO2010096853-A1. |
|
2009 Other Outputs New 1,4-diazepan-2-one derivatives useful for treating, preventing or controlling condition e.g. acne, seborrheic dermatitis, acne vulgaris, acne fulminans, inflammation, and cancersBLASKOVICH M A T and CASSIDY P J (2009). New 1,4-diazepan-2-one derivatives useful for treating, preventing or controlling condition e.g. acne, seborrheic dermatitis, acne vulgaris, acne fulminans, inflammation, and cancers. WO2009105823-A1. |
|
2009 Other Outputs New 1,4-diazepan-2-one derivatives useful for treating, preventing or controlling condition e.g. acne, seborrheic dermatitis, acne vulgaris, acne fulminans, inflammation, and cancersBLASKOVICH M A T and CASSIDY P J (2009). New 1,4-diazepan-2-one derivatives useful for treating, preventing or controlling condition e.g. acne, seborrheic dermatitis, acne vulgaris, acne fulminans, inflammation, and cancers. WO2009105825-A1. |
